title: Evaluating the in vitro susceptibility of bovine mastitis pathogens to a combination of kanamycin and cefalexin: Recommendations for a disk diffusion test.
abstract: Cows suffering from bovine mastitis have markedly reduced milk production because of inflammation within the udder subsequent to infection and damage from bacterial toxins. Antibiotic treatment is commonly used as a preventative and therapeutic measure for bovine mastitis. The most common pathogens include Staphylococcus aureus, various streptococci (Streptococcus dysgalactiae, Streptococcus uberis), and coliforms (Escherichia coli), which can be contracted from other infected cows or from the environment. A combination of kanamycin and cefalexin (1:1.5 wt/wt) is currently used therapeutically in Europe for the treatment of bovine mastitis, although standardized methods for the in vitro determination of the susceptibility of target pathogens have not been developed. This study evaluates the appropriate broth microdilution testing criteria for kanamycin and cefalexin administered in combination and reports the development of a disk diffusion test. At a ratio of kanamycin:cefalexin relevant to that observed in milk postadministration (10:1 wt/wt), the minimum inhibitory concentrations were determined against 307 isolates of target mastitis pathogens (staphylococci, streptococci, and E. coli). Based on achievable concentrations in milk and the resulting distribution of minimum inhibitory concentrations, preliminary broth breakpoints for kanamycin/cefalexin (10:1 fixed ratio) of <or=8/0.8 microg/mL susceptible, 16/1.6 microg/mL intermediate, and >or=32/3.2 microg/mL resistant were applied to evaluated staphylococci, streptococci, and E. coli. Parallel testing by disk diffusion and resulting error-rate bounded analysis using a combined disk concentration of 30 microg of kanamycin and 15 microg of cefalexin resulted in the establishment of preliminary disk interpretive breakpoints of >or=20 mm susceptible, 18 to 19 mm intermediate, and <or=17 mm resistant for staphylococci, streptococci (Strep. uberis and Strep. dysgalactiae only), and E. coli.
authors.affiliation: Eurofins Medinet, Chantilly, VA 20151, USA. chris.pillar@eurofinsmedinet.com
authors.forename: C M
authors.initials: CM
authors.lastname: Pillar
authors.forename: L
authors.initials: L
authors.lastname: Goby
authors.forename: D
authors.initials: D
authors.lastname: Draghi
authors.forename: P
authors.initials: P
authors.lastname: Grover
authors.forename: C
authors.initials: C
authors.lastname: Thornsberry
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002417:Cattle; D002506:Cephalexin / Q000032:analysis / Q000494:pharmacology*; D052978:Disk Diffusion Antimicrobial Tests / Q000379:methods / Q000662:veterinary*; D004338:Drug Combinations; D005260:Female; D007612:Kanamycin / Q000032:analysis / Q000494:pharmacology*; D008414:Mastitis, Bovine / Q000382:microbiology*; D008892:Milk / Q000737:chemistry; D015203:Reproducibility of Results
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007612:Kanamycin; D002506:Cephalexin